Press releases
- Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
- New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
- Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
- Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
- Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
- Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
- Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
- Veracyte Completes Acquisition of C2i Genomics
More ▼
Key statistics
On Friday, Veracyte Inc (12V:DUS) closed at 18.10, 3.43% above its 52-week low of 17.50, set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 18.00 |
---|---|
High | 18.20 |
Low | 17.80 |
Bid | 17.90 |
Offer | 18.20 |
Previous close | 18.00 |
Average volume | 0.00 |
---|---|
Shares outstanding | 78.44m |
Free float | 77.54m |
P/E (TTM) | -- |
Market cap | 1.51bn USD |
EPS (TTM) | -1.02 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 18:30 BST.
More ▼